Johnson & Johnson has proposed paying up to five and a half billion dollars to resolve a long-running wave of lawsuits claiming its talc-based baby powder caused cancer, in what would be one of the largest consumer-product settlements in recent memory.
The company said it would offer as much as three billion dollars next year, with no further payments required before 2028. To take effect, law firms representing ninety-five percent of the ovarian cancer claims in state and federal courts must accept the proposal.
J&J has consistently denied that its talc products cause cancer and has already changed the formula of its widely used powder. Erik Haas, the company's litigation chief, called the allegations meritless and said J&J was settling simply to put the matter behind it and refocus on its medicines.
Lawsuits over the powder began as early as 2009. In a boost for the company earlier this month, a federal court questioned whether individual plaintiffs could prove talc was the direct cause of their illness, a recurring hurdle for claimants.
Talc is a natural mineral found near asbestos, a known carcinogen, and plaintiffs argue contamination made the products dangerous. J&J counters that studies show talc is safe and asbestos-free.
The company's former consumer-health business, Kenvue, now holds responsibility for baby powder sold outside North America. Kenvue, which owns brands including Band-Aid, Listerine and Calpol, was spun off from J&J in 2022.
If approved, the deal would let J&J move on from a saga that has shadowed its reputation, while claimants would trade the uncertainty of further trials for a guaranteed, if contested, payout. The outcome will be watched closely by other firms facing mass tort claims over long-used consumer products.
The market reaction, though measured so far, will be read closely by competitors weighing whether to follow the same playbook or wait for greater certainty.
Behind the headline number lies a structural question about how the sector funds itself, and whether the current model is resilient enough for the cycle ahead.
Investors are weighing the signals against a backdrop of tighter credit and slower growth, where even modest surprises can reset expectations for the quarter.
Rivals are watching the move as a possible template, aware that first-mover advantage in this space can be difficult to dislodge once established.
Regulators, meanwhile, are likely to scrutinise the details, mindful of past episodes where rapid expansion outran the safeguards meant to contain it.
For customers, the practical effect may be subtle at first, surfacing gradually in prices, service, and the choices available to them in the months ahead.
